Overview

High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

Status:
Terminated

Trial end date:
2013-10-31

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. A stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by the chemotherapy and radiolabeled monoclonal antibody. PURPOSE: This randomized phase II trial is studying how well high-dose melphalan works when given with or without radiolabeled monoclonal antibody in treating patients with multiple myeloma undergoing an autologous stem cell transplant.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital Southampton NHS Foundation Trust
University of Southampton

Collaborators:

Bill & Melinda Gates Foundation Visitor Center
European Federation of Pharmaceutical Industries and Associations
NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust
Q-Biologicals NV
The Periscope Consortium

Treatments:

Antibodies
Antibodies, Monoclonal
Immunoglobulins
Melphalan